# C. Ola Landgren

Source: https://onco.cc/people/ola-landgren/  
OnCo record `ola-landgren` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Showed that MGUS precedes essentially all myeloma and leads MRD-driven trials aiming for cure without transplant.

## Summary

Ola Landgren led the prospective studies showing that monoclonal gammopathy of undetermined significance precedes virtually every case of multiple myeloma, defining the disease's precursor states, and now leads MRD-driven trials such as MANHATTAN and the daratumumab-KRd studies that achieve MRD negativity in most patients without transplant. He co-leads the international effort that made MRD an FDA-accepted endpoint.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: myeloma; mrd; precursor
- Role: Chief of Myeloma and Director of the Sylvester Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami
- Specialisms: Multiple myeloma; Minimal residual disease; Precursor conditions (MGUS); Quadruplet therapy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Landgren%20O%5BAuthor%5D%20myeloma%20MRD%20OR%20MGUS

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- targets: [CD38](https://onco.cc/targets/cd38/)
- institutions: [Sylvester Comprehensive Cancer Center, University of Miami](https://onco.cc/institutions/sylvester-miami/)
- key papers: [Jaiswal: clonal haematopoiesis, the pre-leukaemic clones in most people over 70](https://onco.cc/key-papers/paper-jaiswal-chip-nejm-2014/)
- journals: [Blood](https://onco.cc/journals/blood/), [JAMA Oncology](https://onco.cc/journals/jama-oncology/)

---
JSON: https://onco.cc/api/v1/entities/ola-landgren.json